KMT2A and leukemia: UF146 significantly delayed the leukemia onset and led to significant increases in the survival time, extending the median OS from 32 to 42 days (AE9a-driven leukemia model) or 37 to 48 days (MLL-AF9-driven leukemia model) without the body weight loss (Fig. 8a; Supplementary information, Fig. S9a, b).